Drug Trial Radar · NCT07624175
Immunogenicity and Tolerability of Booster Typhoid Conjugate Vaccine (TCV) 5-6 Years After Initial Dose in Children in Burkina Faso
Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
147
Actual
Start
Aug 17, 2024
Primary completion
Oct 26, 2024
Study completion Oct 26, 2024
Sponsor
- Lead sponsor
- Kathleen NeuzilAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Groupe de Recherche Action en Sante
- First posted
- Jun 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 7 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study evaluated the persistence of immunity following primary typhoid conjugate vaccination in early childhood and assessed the immunogenicity and safety of a booster dose administered 5-6 years later. Children previously enrolled in a Phase 2 randomized clinical trial of Vi-tetanus toxoid conjugate vaccine (Vi-TT) were re-enrolled at 6-7 years of age. Participants who previously received Vi-TT received a booster dose of Vi-CRM, while control participants received their first TCV dose. Anti-Vi IgG antibody responses were measured at baseline and 28 days post-vaccination. Safety was assessed through solicited and unsolicited adverse events. This study provides data on durability of TCV immunity and the potential role of booster dosing in endemic settings.
Conditions
- Typhoid
Interventions
Vi capsular polysaccharide-CRM197 conjugate vaccine (Vi-CRM), 0.5 mL IMBiological
Typhoid conjugate vaccine: Vi capsular polysaccharide conjugated to CRM197 carrier protein, administered as 0.5mL intramuscularly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Anti-Vi IgG Antibody Response (Immunogenicity)Time frame: Baseline (Day 0) and Day 28 post-vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Schiphra Protestant Hospital
Ouagadougou, Burkina Faso
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.